DRUG
Larazotide Acetate
AT1001 10 μg/kg/dose up to 500 μg/dose (rounded to the nearest 50 μg) will be administered orally four times a day (QID) to the standard of care for MIS-C.
AT1001 for the Treatment of COVID-19 Related MIS-C
Status
Terminated
Phase
Phase 2
Enrollment
12
Locations
1
Results
Not posted
Publications
0
Study summary
What the protocol is testing.
The primary aim of this study is to evaluate the efficacy and safety of AT1001 versus placebo in pediatric patients with SARS-CoV-2 infection who experience early signs of MIS-C and are at high risk of progression. AT1001 10 μg/kg/dose up to 500 μg/dose (rounded to the nearest 50 μg) or matching placebo will be administered orally four times a day (QID) to the standard of care for MIS-C.
Full detailed description
This is a Phase 2a (Proof of Concept), randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of AT1001 for use in hospitalized pediatric patients diagnosed with MIS-C. Eligible participants (N=20) will be treated with AT1001 or matching placebo orally four times a day (QID) for up to 21 days as an add-on to standard of care. The study includes three phases: * Screening/Baseline: The main purpose of this phase is to determine if the participant meets entry criterion after obtaining informed consent and obtain baseline assessments. * Treatment: Eligible participants will be treated with AT1001 or matching placebo 10 μg/kg/dose QID up to 500 μg/dose (rounded to the nearest 50 μg) for 21 days as an add-on to standard of care for MIS-C. * Follow-up through 24 weeks: The participant will return for a follow-up visits during weekly clinic visits during Week 1 through Week 3, with monthly telemedicine visits at Week 4, Week 8, Week 16 and Week 20, and clinic visits at Week 12 and Week 24. Safety monitoring, including physical examination, vitals, and clinical laboratory testing will be performed during the screening phase, periodically during treatment phase and at the follow-up phase. Adverse events and concomitant medications will be recorded during the entire study. Total duration of the participants' participation in the study is approximately 24 weeks (with 21 days treatment period). Total duration of the study is projected to be 12 months, dependent on enrollment timeline.
Interventions
Treatment arms and agents.
DRUG
Placebo
Matching placebo will be administered orally four times a day (QID) to the standard of care for MIS-C.
Timeline
From registration to results.
First posted
Aug 26, 2021
Study start
Oct 1, 2021
Primary completion
May 15, 2024
Study completion
May 15, 2024
Results posted
Not reported
Registry updated
Jun 13, 2024
Outcomes
What the study measures.
Primary outcomes
Evaluate the efficacy and safety of AT1001 versus placebo on mitigating symptoms of MIS-C
Time frame · 24 weeks
• To evaluate the efficacy and safety of AT1001 versus placebo in pediatric patients with SARS-CoV-2 infection who experience early signs of MIS-C and are at high risk of progression.
Determine proportion of participants with improvement in MIS-C related GI symptoms and no progression of disease
Time frame · 24 weeks
Improvement in GI symptoms is defined as: * Improvement in PedsQL GI Symptoms Scales score ≥48 hours, as determined by patient or caregiver response. * AND improvement in clinical manifestation of GI symptoms, as documented by complete physical exam or clinical assessment and clinical laboratory tests or imaging. No Progression of MIS-C is defined as: * No involvement of additional organ involvement, as identified by clinical assessment and clinical laboratory tests or imaging. * AND no new onset of new or worsening GI symptoms for ≥48 hours including nausea, vomiting, diarrhea, loss of appetite, and/or abdominal pain, as determined by patient or caregiver symptom report or worsening PedsQL GI Symptoms Scales scores.
Secondary outcomes
Determine the impact of AT1001 on infectious and inflammatory markers of MIS-C
Time frame · 24 weeks
Secondary aims of this study include determining the impact of AT1001 on infectious and inflammatory markers of MIS-C.
Determine the impact of AT1001 on improvement in MIS-C symptoms for ≥48 hours, as determined by patient or caregiver symptom report on MIS-C Symptom Questionnaire.
Time frame · 24 weeks
Determine the impact of AT1001 on length of stay in hospital (days from baseline to readiness to discharge).
Time frame · 24 weeks
Determine the impact of AT1001 on re-presentation to medical care for MISC-related symptoms after discharge.
Time frame · 24 weeks
Determine the impact of AT1001 on need for escalation of care (eg, transfer from hospital ward to ICU; supplemental oxygen; mechanical ventilation).
Time frame · 24 weeks
Transfer from hospital ward to ICU; supplemental oxygen; mechanical ventilation.
Determine the impact of AT1001 on change from baseline in additional organ system(s) involvement during acute presentation/hospitalization, as identified by clinical assessment and clinical laboratory tests.
Time frame · 24 weeks
Determine the impact of AT1001 on change from baseline in levels of IgM, IgG, and IgA antibodies against SARS CoV-2.
Time frame · 24 weeks
Determine the impact of AT1001 on change from baseline in levels of inflammatory markers (CRP, d-dimer, ferritin).
Time frame · 24 weeks
Determine the impact of AT1001 on normalization of SARS-CoV-2 Spike, S1 and nucleocapsid.
Time frame · 24 weeks
Determine the impact of AT1001 on change from baseline in levels of zonulin.
Time frame · 24 weeks
Eligibility
Who can take part.
- Minimum age
- 1 Month
- Maximum age
- 21 Years
- Sex
- ALL
- Healthy volunteers
- No
Inclusion Criteria: 1. Pediatric patients with or without comorbidity 2. Age ≥ 1 month to \< 21 years 3. Confirmed MIS-C by signs and symptoms as detailed by the CDC Health Advisory (https://www.cdc.gov/mis-c/hcp/; May 14, 2020) 1. Persistent fever/chills (\>38.0°C for ≥24 hours, or report of subjective fever lasting ≥24 hours); AND 2. One or more laboratory parameters (evidence of inflammation); AND, i) elevated C-reactive protein (CRP) ii) elevated erythrocyte sedimentation rate (ESR) iii) elevated ferritin iv) elevated lactic acid dehydrogenase (LDH) v) elevated d-dimer vi) elevated fibrinogen vii) elevated procalcitonin viii) elevated interleukin 6 (IL-6) ix) increased neutrophils x) reduced lymphocytes xi) low albumin c) Evidence of clinically severe illness requiring hospitalization, with multisystem (\>2) organ involvement (cardiac, renal, respiratory, hematologic, gastrointestinal, dermatologic, or neurological)-MUST include GI symptoms, such as nausea, vomiting, diarrhea and/or abdominal pain; AND, d) No alternative plausible diagnoses; AND e) Positive for current or recent SARS-CoV-2 infection by RT-PCR, serology, or antigen test 4. Subject (or legal authorized representative) capable of understanding and signing an informed consent form and assent form, when appropriate. Exclusion Criteria: 1. Female participants pregnant and/or lactating. 2. Female participant has childbearing potential and is unwilling to use an acceptable method of birth control for the duration of the study. 3. Participant has a significant co-morbid disease that by the Investigator's determination would make the participant unsuitable for enrollment, including unstable medical conditions. 4. Participation in any other clinical investigation using an experimental drug within 30 days prior to screening or intends to participate in another clinical study while participating in AT1001 MIS-C 101 study. 5. Have participated in a blood/plasma donation or blood loss greater than 400 mL within 90 days, or greater than 200 mL within 30 days prior to Screening. 6. Known hypersensitivity to any of the formulation components of AT1001.
Study locations
1 registered sites.
United States. Showing up to 24 locations stored in the fast local snapshot.
Massachusetts General Hospital
Boston, Massachusetts, United States
Publications
Results and literature.
No PMID-linked publications were present in this registry snapshot.
Related trials
More studies on Larazotide.
NCT IDStudyPhase / statusEnrollmentUpdated
A Study of Patients With Fabry Disease (US Specific)
Amicus Therapeutics · Fabry Disease
Not applicable
Recruiting
450
2026-07
A Study to Evaluate Migalastat in Fabry Subjects With Amenable GLA Variant and Renal Disease
Amicus Therapeutics · Fabry Disease
Phase 3
Active, not recruiting
14
2026-07
A Study of Migalastat in Pediatric Subjects (2 to <12 Yrs) With Fabry Disease and Amenable GLA Variants
Amicus Therapeutics · Fabry Disease
Phase 3
Recruiting
8
2026-06
AT1001 for the Treatment of Long COVID
Massachusetts General Hospital · Long COVID · Long COVID-19
Phase 2
Active, not recruiting
107
2026-05
Safety, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged >12 Years) With Fabry Disease
Amicus Therapeutics · Fabry Disease
Phase 3
Completed
16
2026-02
Physician Initiated Expanded Access Request for Migalastat in Individual Patients With Fabry Disease
Amicus Therapeutics · Fabry Disease
Not applicable
Available
—
2025-07
Study to Evaluate the Efficacy and Safety of Larazotide Acetate for the Relief of CeD Symptoms
9 Meters Biopharma, Inc. · Celiac Disease
Phase 3
Terminated
307
2022-07
Safety, Pharmacokinetics, Pharmacodynamics, and Efficacy of Migalastat in Pediatric Subjects (Aged 12 to <18 Years)
Amicus Therapeutics · Fabry Disease
Phase 3
Completed
22
2021-11
Related PeptideStat pages
Put the record in context.
Research pages describe evidence. Vendor pages, where available, describe independently tracked research-product listings and are not clinical recommendations.